argenex (NASDAQ:ARGX) Earns “Buy” Rating from DZ Bank

argenex (NASDAQ:ARGX)‘s stock had its “buy” rating reaffirmed by analysts at DZ Bank in a research note issued to investors on Friday.

Other research analysts also recently issued research reports about the company. UBS Group raised argenex from a “neutral” rating to a “buy” rating and increased their target price for the stock from $960.00 to $1,400.00 in a report on Wednesday, August 26th. HC Wainwright boosted their price target on argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Truist Financial boosted their price target on argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings lowered argenex from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 23rd. Finally, Wells Fargo & Company upped their price target on argenex from $1,350.00 to $1,415.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,158.32.

argenex Stock Performance

Shares of ARGX stock traded down $8.70 during trading hours on Friday, hitting $816.33. 115,361 shares of the company were exchanged, compared to its average volume of 345,069. argenex has a one year low of $661.85 and a one year high of $1,072.75. The business’s 50-day simple moving average is $959.93 and its two-hundred day simple moving average is $877.49. The stock has a market capitalization of $51.07 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 0.86 and a beta of 0.44.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. As a group, analysts anticipate that argenex will post 28.83 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its stake in argenex by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares during the period. Sands Capital Management LLC raised its position in shares of argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after buying an additional 340,245 shares in the last quarter. Jennison Associates LLC raised its position in shares of argenex by 3.4% during the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock worth $173,411,000 after buying an additional 7,707 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of argenex by 1.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock worth $130,277,000 after buying an additional 2,579 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of argenex by 98.9% in the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after acquiring an additional 53,293 shares during the period. 60.32% of the stock is currently owned by institutional investors.

About argenex

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).